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Aims. To investigate how circulating microvesicle phenotypes correlate with insulin sensitivity, body composition, plasma lipids,
and hepatic fat accumulation. We hypothesized that changes elicited by testosterone replacement therapy are reflected in levels of
microvesicles. Methods. Thirty-nine type 2 diabetic males with lowered testosterone levels were assigned to either testosterone
replacement therapy or placebo and evaluated at baseline and after 24 weeks. Microvesicles were analysed by flow cytometry
and defined as lactadherin-binding particles within the 0.1–1.0𝜇m gate. Microvesicles of platelet, monocyte, and endothelial cell
origin were identified by cell-specific markers and their expression of CD36 was investigated. Results. Triglycerides correlated
positively with all investigated microvesicle phenotypes in this study (𝑝 < 0.05), and indicators of hepatic fat accumulation,
alanine aminotransferase, and gamma glutamyltransferase correlated with platelet and endothelial microvesicles and CD36-
expressing microvesicles from platelets and monocytes (𝑝 < 0.05). BMI, waist circumference, and fat percentage correlated
with CD36-expressing monocyte microvesicles (𝑝 < 0.05), while insulin sensitivity did not correlate with any microvesicle
phenotypes.Microvesicle levels were unaffected by testosterone therapy.Conclusions.Metabolic syndrome components and hepatic
fat accumulation correlated with microvesicle phenotypes, supporting the involvement of especially CD36 on monocytes in
metabolic syndrome pathogenesis. Although testosterone therapy improved body composition measures, microvesicle phenotype
levels were unaffected. This trial was registered at ClinicalTrials.gov (NCT01560546).
1. Introduction
The metabolic syndrome (MetSy) is constituted by a range
of metabolic abnormalities including abdominal adiposity,
insulin resistance, hypertension, and dyslipidaemia [1], all
of which are associated with an increased risk for type
2 diabetes mellitus (T2D) [2] and cardiovascular disease
(CVD) [3]. Given its increasing prevalence and themorbidity
and mortality associated with MetSy, there is an urgent need
to understand the underlying mechanisms of MetSy.
It is commonly agreed upon that insulin resistance is
the central feature in describing the pathophysiology of
MetSy [1].Thedevelopment of insulin resistance seems highly
attributable to an overabundance of circulating fatty acids
and ectopic lipid storage [4] leading to inflammation and
oxidative stress [5]. Collectively, these alterations contribute
to the development of the structural anomalies and car-
diovascular complications associated with MetSy, including
endothelial dysfunction, atherosclerosis, and thrombosis.
Furthermore, low testosterone and sex hormone-binding
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globulin in men has been linked with the MetSy and T2D
[6]. Testosterone replacement therapy (TRT) has previously
been demonstrated to improve lean body mass, total fat
mass, total cholesterol, and LDL cholesterol in men with
T2D [7]. However, a more recent trial could not demonstrate
any improvements in the plasma lipid profile nor glycaemic
control in T2D patients receiving TRT [8]. Thus, the car-
diometabolic benefits with special emphasis on ectopic lipid
deposition of TRT remain uncertain.
Changes in levels of certain subgroups of circulating
microvesicles (MVs) have previously been ascribed to MetSy
[9] and several of its components including insulin resis-
tance, hypertension, hyperlipidaemia, oxidative stress, and
waist circumference [10]. MVs are a heterogeneous group
of membrane-encapsulated particles that contain cellular
components and are released by cells in latent, activated, and
apoptotic states [11]. Therefore, a rapidly growing number of
studies have recently started to recognize the role of MVs
and their potential as biomarkers in a number of diseases. In
addition, CD36 is a scavenger receptor and a fatty acid trans-
porter present in most cell phenotypes including platelets
[12], endothelial cells [13], and monocytes [14]. Increased
levels of circulating CD36 have previously been associated
with unhealthy fat distribution [15], atherosclerosis [16],
insulin resistance [17], and fatty liver [18], all attributable to
ectopic deposition of fat. Thus, measuring the expression of
CD36 on MVs could yield important information regarding
improvements in the abovementioned components.
The aim of this study was to address the hypotheses that
levels of specific phenotypes of MVs correlate with compo-
nents of MetSy and markers for hepatic fat accumulation and
that improvements elicited by TRT affect MV phenotypes in
aging, testosterone deficient males with T2D. Testosterone
deficient adult males diagnosed with T2D were recruited and
randomly assigned to TRT or placebo groups. Circulating
MVs of platelet, endothelial, and monocyte origin were
quantified in peripheral blood, and their expression of surface
CD36 was determined as a surrogate marker for ectopic
fat accumulation. Potential relationships were investigated
between levels of MV subpopulations and body composition,
hepatic fat accumulation, plasma lipids, and insulin resistance
prior to the treatment regime, and changes in the levels of
MV phenotypes over the trial period were finally compared
between TRT and placebo groups.
2. Methods
2.1. Ethical Aspects. The present study was registered at
ClinicalTrials.gov (NCT01560546) and approved by the local
ethics committee and the Danish Health and Medicines
Authority. All patients gave written informed consent prior
to inclusion.
2.2. Subjects. This study was conducted on thirty-nine Cau-
casian men between 50 and 70 years of age, diagnosed
with type 2 diabetes within the past ten years, treated with
Metformin for ≥3 months, and with bioavailable testos-
terone levels <7.3 nmol/L. Exclusion criteria were glycated
haemoglobin (HbA1C) ≥ 9.0%, BMI ≥ 40 kg/m
2, severe
hypertension, cardiovascular, lung, or kidney disease, pri-
mary or secondary hypogonadism, knownmalignant disease,
haematocrit > 50%, PSA > 3 𝜇g/L, abnormalities in routine
blood tests, nocturia > 3 times/night, significant ECG abnor-
malities, severe active mental disease, current or previous
drug abuse, or the desire to have children [8].
2.3. Study Design. This trial was double-blinded, ran-
domized, and placebo-controlled by design and has been
described previously [8]. Briefly, subjects were randomly
assigned to either TRT or placebo groups and subjected to
a 24-week treatment regime with either Testim 1% testos-
terone gel or placebo, respectively. Testim 1% testosterone
gel, a transdermal testosterone preparation, was supplied in
tubes containing 50mg testosterone each and applied to the
shoulders and upper arms at the same time of day throughout
the trial period. The initial dosage was 50mg/day and was
adjusted according to plasma testosterone concentration after
three weeks to a maximum of 100mg/day. Subjects were eval-
uated at baseline and after 24weeks. During each visit, height,
weight, waist and hip circumference, blood pressure, and
biochemical characteristics were recorded, and venous blood
samples were collected in the fasting state for flow cytometric
analysis of MVs. In addition regional body composition was
determined by dual energy X-ray absorptiometry (DXA).
Insulin sensitivity was determined with the euglycaemic,
hyperinsulinaemic clamp technique.
2.4. Fluorescent Labelling of MVs. Blood samples for flow
cytometric analysis of MVs were collected into tubes
containing sodium citrate anticoagulant at a 3.2% (0.105M)
final concentration and the first centrifugation cycle was
initiated within one hour after collection. Samples were
subjected to a two-step centrifugation protocol to obtain
platelet-free plasma (PFP): an initial centrifugation step at
1800×g for 10 minutes at room temperature, followed by an
additional centrifugation step of the supernatant at 3000×g
for 15 minutes. PFP was stored at −80∘C until analysis. 50𝜇L
of freshly thawed plasma was transferred to TruCount tubes
(BD Bioscience, NJ, USA) in order to allow quantitation of
measured events. Samples were incubated for 30 minutes at
4∘C in the dark with 5 𝜇L fluorescein isothiocyanate- (FITC-)
conjugated bovine lactadherin (83 𝜇g/mL, Hematologic
Technologies Inc., VT, USA), 3 𝜇L allophycocyanin- (APC-)
conjugated anti-human CD41 (6 𝜇g/mL IgG1, 𝜅 (clone HIP8,
BioLegend, San Diego, CA, USA)), 10𝜇L phycoerythrin-
(PE-) conjugated anti-human CD14 (60 𝜇g/mL IgG2a (clone
TÜK4, DAKO,Denmark)), 20 𝜇L PE-conjugated anti-human
CD62E (100 𝜇g/mL IgG1, 𝜅 (clone 68-5H11, BD Pharmingen,
New Jersey, USA)), and either 4𝜇L phycoerythrin- (PE-)
conjugated anti-human CD36 (25𝜇g/mL IgG2a, 𝜅 (clone
5–271, BioLegend, San Diego, CA, USA)) or 20𝜇L APC-
conjugated anti-human CD36 (6,25𝜇g/mL IgM, 𝜅 (clone
CB38, BD Pharmingen, New Jersey, USA)), used when
appropriate. Isotype controls matching each antibody were
used as negative controls. After incubation, samples were
diluted in 200 𝜇L Dulbecco’s phosphate buffered saline
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Figure 1: Gating strategy for the flow cytometric microvesicle assay. (a) A 0.1–1.0 𝜇m size gate was defined using silica beads. (b) Unlabelled
plasma samples and isotype controls were used to establish gates in the fluorescence channels. (c) MVs were defined as phosphatidylserine
expressing (PS+) particles based on their ability to bind lactadherin within the 0.1–1.0𝜇m gate. (d–f) CD41-APC, CD62E-PE, and CD14-PE
antibodies were used to identify MVs of platelet (d), endothelial (e), and monocyte (f) origin, respectively, and their expression of CD36 was
investigated using either CD36-PE or CD36-APC antibodies, as appropriate.
0.0095M PO4 (PBS) buffer (Lonza, Basel, Switzerland) that
had been filtered through a sterile 0.2𝜇m Q-Max syringe
filter (Frisenette, Knebel, Denmark).
2.5. Flow Cytometric Measurement of MVs. Flow cytometric
analysis of plasma MV content was performed according to
a recently described protocol [19] on a BD FACSAria III
High Speed Cell Sorter (BD Biosciences, San Jose, CA, USA)
at a maximal rate of 2 × 104 events per second until 106
events were collected in total. Data processing was performed
as demonstrated in Figure 1. A size gate encompassing
approximately 100 nm to 1000 nmwas established in FlowJo
software (v. 10.0.8, Tree Star, Inc., Oregon, USA) using the
“Autogate” function around 200 nm and 900 nm fluorescent,
size calibrated beads on log-scaled forward scatter height
(FSC-H), and side scatter height (SSC-H). In addition, a
discriminator was set at 200 on SSC-H to avoid exclusion of
the smallest events. MVs were defined as phosphatidylserine
positive (PS+) events based on binding of lactadherin-FITC
within the established size gate. MVs of platelet origin were
defined as CD41 positive events; monocyte MVs (MMVs)
were defined as CD14 positive events; endothelial MVs
(EMVs) were defined as CD62E positive events, and the
expression of CD36 was investigated on PMVs, MMVs, and
EMVs.
2.6. Data Analysis. All data analyses were conducted in
R 3.2.2 (R Core Team, Vienna, Austria). The assumption
of normality was tested with Shapiro-Wilk’s 𝑊 test for
each parameter and visually confirmed. Observations were
compared within the respective groups with paired Student’s
𝑡-test or pairedWilcoxon signed ranks test where appropriate.
Bivariable correlations between MV subpopulations and
anthropometric, biochemical, and clamp parameters were
studied using Spearman’s ranked correlation coefficients (𝑟𝑆)
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Table 1: Baseline characteristics of study population.
Placebo (𝑛 = 19) Testosterone (𝑛 = 20) 𝑝
Age 59,5 (6,3) 61,4 (6) 0,3367
Smoking status (current/previous/never)† 4/9/6 3/12/4
BMI (kgm−2) 30,8 (3,8) 30,6 (4) 0,8879
Waist circumference (cm) 105,8 (10,8) 106,9 (10) 0,7577
Total fat mass (kg) 27,9 (6,5) 26,9 (22,6; 34,8) 0,7837
Lean body mass (kg) 61,7 (7,5) 61,9 (8,9) 0,9531
Systolic blood pressure (mmHg) 138,2 (12,8) 137,7 (16,7) 0,9151
Diastolic blood pressure (mmHg) 81,7 (8,2) 80,5 (11,1) 0,6948
HbA1c (% Hb) 6,50 (6,15; 6,80) 6,52 (0,53) 0,8108
Total cholesterol (mmol L−1) 3,8 (1,1) 4,0 (0,7) 0,5511
LDL (mmol L−1) 2,2 (0,8) 2,3 (0,7) 0,6904
HDL (mmol L−1) 0,9 (0,9; 1) 1,0 (0,2) 0,2057
TG (mmol L−1) 1,3 (1,16; 1,58) 1,1 (0,85; 2,05) 0,323
ALT (IU L−1) 31,0 (24,5; 43) 35,7 (17,5) 0,844
GGT (IUL−1) 39,0 (30; 51,5) 31,0 (23,75; 39,25) 0,1123
Fasting glucose (mmol L−1) 6,92 (1,01) 7,14 (1,27) 0,5602
Disposal rate: base 90,0 (12,8) 88,6 (85,39; 109,02) 0,3506
Disposal rate: clamp 179,4 (42,1) 155,9 (136,34; 198,84) 0,5877
ΔRd‡ 89,4 (40,6) 89,8 (14,9) 0,9655
HGP: base 83,2 (13,2) 89,8 (14,9) 0,1516
HGP: clamp 32,2 (24,57; 38,64) 28,9 (22,02; 40,88) 0,7284
C-peptide: base 1127,8 (318,7) 933,5 (859,25; 1306) 0,422
Insulin: fasting 103,8 (55,9) 89,5 (47,8) 0,4028
Insulin clearance 0,4 (0,1) 0,3 (0,28; 0,33) 0,1912
Data are depicted as mean (SD) or median (Q25%; Q75%).
†Smoking status for 1 person in the testosterone group is unknown. ‡Difference in disposal rate at
baseline and during clamp.
due to nonnormal distribution of MV parameters. All 𝑝
values reported are two-sided, and statistical significance was
defined as 𝑝 < 0.05.
3. Results
3.1. Characterization of Study Subjects. Demographic charac-
teristics of the subjects were previously described by Mag-
nussen et al. [8] and are summarized in Table 1. Of the thirty-
nine subjects enrolled in this study, twenty were assigned to
TRT and nineteen to placebo. In the initial assessment, no
significant differences existed between TRT and placebo.
3.2. Body Composition and Markers for Hepatic Fat Accumu-
lation. Correlations between components of MetSy and MV
phenotypes are listed in Table 2. CD36+MMVswere the only
MV subpopulation found to be significantly correlated with
BMI (𝑟𝑆 = 0.35, 𝑝 < 0.05), waist circumference (𝑟𝑆 = 0.34,
𝑝 < 0.05), and fat % (𝑟𝑆 = 0.33, 𝑝 < 0.05). No correlations
between lean body mass and any MV phenotypes could
be reported, however. Positive correlations were identified
between MVs and ALT and between GGT and PMVs (𝑟𝑆 =
0.43, 𝑝 < 0.01), CD36+ PMVs (𝑟𝑆 = 0.38, 𝑝 < 0.05), and
EMVs (𝑟𝑆 = 0.33, 𝑝 < 0.05). Furthermore, CD36+ MMVs
correlated positively with both ALT (𝑟𝑆 = 0.34, 𝑝 < 0.05) and
GGT (𝑟𝑆 = 0.42, 𝑝 < 0.01).
3.3. Plasma Lipid Profile. Positive correlationswere identified
between total cholesterol and PMVs (𝑟𝑆 = 0.48, 𝑝 < 0.01)
and CD36+ PMVs (𝑟𝑆 = 0.49, 𝑝 < 0.01). Moreover, CD36+
PMVs were positively correlated with LDL cholesterol (𝑟𝑆 =
0.37, 𝑝 < 0.05). Triglycerides correlated positively with MVs
(𝑟𝑆 = 0.43, 𝑝 < 0.01), PMVs (𝑟𝑆 = 0.58, 𝑝 < 0.001), CD36+
PMVs (𝑟𝑆 = 0.51, 𝑝 < 0.01), EMVs (𝑟𝑆 = 0.38, 𝑝 < 0.05),
CD36+ EMVs (𝑟𝑆 = 0.41, 𝑝 < 0.05), MMVs (𝑟𝑆 = 0.50, 𝑝 <
0.01), andCD36+MMVs (𝑟𝑆 = 0.45,𝑝 < 0.01).No significant
correlationswere identified betweenHDLandMVs, however.
3.4. Insulin Sensitivity. Fasting insulin levels correlated posi-
tively with MVs (𝑟𝑆 = 0.36, 𝑝 < 0.05) and MMVs (𝑟𝑆 = 0.41,
𝑝 < 0.05), and both fasting levels of insulin (𝑟𝑆 = 0.54, 𝑝 <
0.001) and C-peptide (𝑟𝑆 = 0.43, 𝑝 < 0.01) correlated posi-
tively with CD36+ MMVs. No other significant correlations
could be identified between MV phenotypes and parameters
associated with insulin sensitivity.
3.5. TRT. The effect of TRT on the patient population of
this study has been described elsewhere [8]. In brief, TRT
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Figure 2: Plasma levels of different MV phenotypes in placebo (𝑛 = 19, dark grey) and TRT (𝑛 = 20, light grey) groups at baseline and after
24 weeks of treatment. Outliers are represented as filled circles.
significantly increased lean body mass (𝑝 < 0.001) and
decreased total fat mass (𝑝 = 0.0125), fat % (𝑝 < 0.001), and
HDL (𝑝 = 0.006). No other parameters were affected by TRT.
Furthermore, TRT did not affect any of the investigated MV
phenotypes (Figure 2).
4. Discussion
Theresults of this study are twofold. First, specific phenotypes
of MVs correlated with waist circumference, plasma triglyc-
erides, total cholesterol, and LDL to a certain extent, and
putativemarkers for hepatic fat accumulation, includingALT,
and GGT. CD36+MMVs were of particular significance, and
the results of this study are in support of current evidence
on the role of monocytes in the pathophysiology of MetSy
and T2D. Second, although TRT resulted in improved lean
bodymass, total fat mass, and fat %, levels of circulatingMVs
remained unaltered.
By analysing relationships between levels of circulating
MVs and components of MetSy and T2D, CD36+ MMVs
were revealed to correlate with several measures of body
composition. In obesity, adipose tissue monocytes undergo
a phenotypic switch and are polarized toward a proin-
flammatory state [20]. Additionally, distinct differences in
monocyte-derived macrophages and inflammatory cytokine
profiles have been identified between different adipose tissue
depots [5]. Furthermore, expression of CD36 on monocytes
is increased in obesity [21], and a large body of evidence
suggests that polarization of monocytes is mediated by CD36
[14].Thus, it is possible that the increased expression of CD36
on the surface of monocytes and their polarization result in
increased MV release and that the expression of CD36 on
MMVs is equally increased.
Interestingly, PMVs and EMVs were uncorrelated with
measures of body composition in the present study. Con-
versely, several studies have previously identified relation-
ships between PMV and EMV phenotypes and different
measures of body composition including BMI, waist cir-
cumference, and total fat mass [22]. These associations have
previously been attributed to oxidative stress present in
obesity [10], as BMI, waist circumference, and total fat mass
correlate well withmarkers for oxidative stress [23]. However,
thesemeasures do not take into account the distribution of fat
in the different adipose tissue compartments. Furthermore,
the different adipose tissue compartments display distinct
inflammatory characteristics [5].Therefore, it would arguably
be more accurate to analyse relationships between levels
of MVs and the volumes of the different adipose tissue
compartments.
In the present study, GGT was found to correlate posi-
tively with PMVs, CD36+ PMVs, EMVs, and CD36+MMVs,
and, additionally, ALT correlated positively with CD36+
MMVs. In the presence of hepatic lipid accumulation, it has
been reported that hepatic gluconeogenesis and fatty acid
oxidation are increased [24], which in turn could be related to
liver damage due to a buildup of reactive oxygen species [25].
This results in increased secretion of circulating triglycerides
and liver enzymes [26]. GGT andALT are liver transaminases
that are released into circulation in conditions that comprise
damage of hepatocytes. One such condition is nonalcoholic
fatty liver disease (NAFLD), andALT andGGT are often used
to predict the risk of incident T2D and CVD in these patients
[27]. Thus, this result further supports the involvement of
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monocytes and their expression of CD36 in the pathogenesis
of MetSy, T2D, and their related complications.
PMVs and CD36+ PMVs were found to correlate posi-
tively with total cholesterol, while only CD36+ PMVs cor-
related positively with LDL cholesterol. Studies have previ-
ously demonstrated that elevated levels of total cholesterol
and LDL cholesterol in familial hypercholesterolemia are
associated with increased thrombotic activity and platelet
function [28]. Recently, plasma levels of total cholesterol have
been associated with an increase in mean platelet volume
[29], which reflects increased activation, metabolic reactivity,
and coagulability [30]. Furthermore, as a consequence of
oxidative stress present in MetSy and T2D, LDL becomes
oxidized (oxLDL) and accumulates in the circulatory system.
oxLDL has previously been implicated in activating platelets
throughmechanisms involving CD36 [31]. CD36 is expressed
abundantly on the surface of platelets, and activation of
platelets has been demonstrated to increase surface expres-
sion of CD36 by exocytosis of intracellular 𝛼-granules [32].
Furthermore, oxLDL has previously been demonstrated to
increase EMV release [33]; however the finding that EMVs in
the present study are unrelated to total cholesterol and LDL
cholesterol suggests that this association could be influenced
by confounding factors such as diabetes.
Another interesting observation was that all of the inves-
tigated MV phenotypes in the present study correlated with
circulating triglycerides. One of the main sources of triglyc-
erides in the circulatory system is lipoprotein particles with
high concentrations of triglycerides such as very low density
lipoproteins (VLDL) [34]. VLDL has been demonstrated to
induce platelet hyperreactivity in an in vitro setting [35]. In
addition, previous studies have demonstrated that increased
levels of EMVs are highly associated with circulating triglyc-
erides [22]. High levels of triglycerides have previously been
implicated in impaired endothelial function [36] through
mechanisms most likely associated with remnant lipoprotein
particles [37] and the production of reactive oxygen species
[38]. Taken together, it can be argued that dyslipidaemia
affects platelets and endothelial cells and that this is reflected
in levels of circulating MVs.
We identified positive associations between MMVs and
CD36+ MMVs on the one hand and fasting insulin levels
on the other. Additionally, CD36+ MMVs also correlated
positively with basal levels of C-peptide. The development
of insulin resistance has been highly ascribed to an over-
abundance of fatty acids as well as ectopic lipid storage [4].
Furthermore, the phenotypic shift observed in monocytes
in obesity is thought to contribute to the development of
insulin resistance and T2D (reviewed in [39]). This result
therefore further supports the involvement of monocytes in
the pathogenesis ofMetSy and T2D.However, caution should
be applied when interpreting results concerning insulin
resistance in the participants of this study. Apart fromMMVs,
no other MV phenotypes were associated with measures of
insulin resistance. Apossible explanation for this is that the all
participants were all prescribed treatment with Metformin,
an inhibitor of hepatic glucose output [40]. Through its
action in limiting hyperglycaemia, Metformin can therefore
be considered a possible confounder that influences the levels
of MVs.
In spite of TRT eliciting mild but significant improve-
ments in lean body mass, total fat mass, and fat % in the
present study, no significant changes could be observed in
any of the studiedMV subpopulations. It is important to note
that, while TRT elicited mild changes in the abovementioned
parameters, most parameters that were found to correlate
with the investigated MV phenotypes were unaffected. Thus,
it is unlikely that the MV phenotypes included in the present
study are affected by TRT.
A number of limitations with this study should be consid-
ered. Although the number of participants were determined
beforehand to be more than 15 in each group to result in a
minimum relevant effect size of 1,3 kg in lean body mass [41]
with a 5% probability for type 1 error and 10% probability
of a type 2 error, the authors acknowledge that the number
of participants in this study is a limitation. Therefore, while
some of our findings were statistically significant, several
of the null findings might be a consequence of the sample
size. Another possible limitation of the present study is that
correlations between baseline parameters cannot provide
information about causality due to the cross-sectional nature
of the analysis and should therefore purely be regarded as
hypothesis generating. Finally, due to the highly homogenous
nature of the study participants and the lack of a healthy
control group, it is uncertain how the results of this study
would translate to the overall population, and therefore
generalization of these findings should be done with caution.
In conclusion, we demonstrated that the MV phenotypes
investigated in this study correlated with several of the
components ofMetSy andT2D,whereCD36+MMVswere of
particular importance. Our findings are therefore in support
of the suggested role of monocytes as protagonists in the
pathogenesis of the metabolic syndrome and T2D. It can be
inferred that the activation of and shift in monocyte polarity
from an anti-inflammatory to a proinflammatory phenotype
upon increased ectopic fat deposition are mediated by CD36,
which in turn leads to increased expression of CD36 on
the plasma membrane [5, 14, 20, 21]. This activation accom-
panied by cell stress caused by the production of reactive
oxygen species results in increased budding of the plasma
membrane and release of MVs (reviewed in [11]). Taken
together, increased numbers of CD36+ MMVs can therefore
be proposed as possible blood-based biomarkers for ectopic
fat accumulation in obesity, MetSy, and T2D.We additionally
demonstrated that TRT did not result in altered levels of
the investigatedMV phenotypes, even though improvements
were seen in lean body mass and total fat mass. It could,
however, be argued that the changes in body composition
elicited by TRT are mild, and it remains to be demonstrated
whether TRT improves ectopic fat deposition and thereby
cardiovascular health in patients with T2D. However, it
cannot be excluded that the limitations of this study played
a role in the latter result. Therefore, the authors of this
study suggest that further studies are warranted in which the
limitations of the present study are addressed to assess the
direct effects of TRT on cardiovascular health in men with
T2D.
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[11] C. Théry, M. Ostrowski, and E. Segura, “Membrane vesicles as
conveyors of immune responses,” Nature Reviews Immunology,
vol. 9, no. 8, pp. 581–593, 2009.
[12] A. Zimman andE.A. Podrez, “Regulation of platelet function by
class B scavenger receptors in hyperlipidemia,” Arteriosclerosis,
Thrombosis, and Vascular Biology, vol. 30, no. 12, pp. 2350–2356,
2010.
[13] H. Adachi andM. Tsujimoto, “Endothelial scavenger receptors,”
Progress in Lipid Research, vol. 45, no. 5, pp. 379–404, 2006.
[14] D. J. Kennedy and S. R. Kashyap, “Pathogenic role of scavenger
receptor CD36 in the metabolic syndrome and diabetes,”
Metabolic Syndrome andRelatedDisorders, vol. 9, no. 4, pp. 239–
245, 2011.
[15] L. Knøsgaard, S. B.Thomsen,M. Støckel, H. Vestergaard, andA.
Handberg, “Circulating sCD36 is associated with unhealthy fat
distribution and elevated circulating triglycerides in morbidly
obese individuals,” Nutrition & Diabetes, vol. 4, article e114,
2014.
[16] M. H. Nielsen, H. Irvine, S. Vedel, B. Raungaard, H. Beck-
Nielsen, and A. Handberg, “Elevated atherosclerosis-related
gene expression,monocyte activation andmicroparticle-release
are related to increased lipoprotein-associated oxidative stress
in familial hypercholesterolemia,” PLoS ONE, vol. 10, no. 4,
Article ID e0121516, 2015.
[17] A. Handberg, K. Levin, K. Højlund, and H. Beck-Nielsen,
“Identification of the oxidized low-density lipoprotein scav-
enger receptor CD36 in plasma: a novel marker of insulin
resistance,” Circulation, vol. 114, no. 11, pp. 1169–1176, 2006.
[18] A. Handberg, K. Højlund, A. Gastaldelli et al., “Plasma sCD36
is associated with markers of atherosclerosis, insulin resistance
and fatty liver in a nondiabetic healthy population,” Journal of
Internal Medicine, vol. 271, no. 3, pp. 294–304, 2012.
[19] M. H. Nielsen, H. Beck-Nielsen, M. N. Andersen, and A. Hand-
berg, “A flow cytometric method for characterization of circu-
lating cell-derived microparticles in plasma,” Journal of Extra-
cellular Vesicles, vol. 3, pp. 1–12, 2014.
[20] C. N. Lumeng, J. L. Bodzin, and A. R. Saltiel, “Obesity induces a
phenotypic switch in adipose tissue macrophage polarization,”
Journal of Clinical Investigation, vol. 117, no. 1, pp. 175–184, 2007.
[21] S. R. Kashyap, A. G. Ioachimescu, H. L. Gornik et al., “Lipid-
induced insulin resistance is associated with increased mono-
cyte expression of scavenger receptor CD36 and internalization
of oxidized LDL,” Obesity, vol. 17, no. 12, pp. 2142–2148, 2009.
[22] N. Amabile, S. Cheng, J. M. Renard et al., “Association of
circulating endothelial microparticles with cardiometabolic
risk factors in the Framingham Heart Study,” European Heart
Journal, vol. 35, no. 42, pp. 2972–2979, 2014.
[23] S. Furukawa, T. Fujita,M. Shimabukuro et al., “Increased oxida-
tive stress in obesity and its impact on metabolic syndrome,”
Journal of Clinical Investigation, vol. 114, no. 12, pp. 1752–1761,
2004.
[24] N. E. Sunny, E. J. Parks, J. D. Browning, and S. C. Burgess,
“Excessive hepatic mitochondrial TCA cycle and gluconeo-
genesis in humans with nonalcoholic fatty liver disease,” Cell
Metabolism, vol. 14, no. 6, pp. 804–810, 2011.
[25] S. Satapati, N. E. Sunny, B. Kucejova et al., “Elevated TCA
cycle function in the pathology of diet-induced hepatic insulin
resistance and fatty liver,” Journal of Lipid Research, vol. 53, no.
6, pp. 1080–1092, 2012.
Journal of Diabetes Research 9
[26] H. Yatsuya, T. Nihashi, Y. Li et al., “Independent association of
liver fat accumulation with insulin resistance,” Obesity Research
& Clinical Practice, vol. 8, no. 4, pp. e350–e355, 2014.
[27] N. Ghouri, D. Preiss, and N. Sattar, “Liver enzymes, nonalco-
holic fatty liver disease, and incident cardiovascular disease: a
narrative review and clinical perspective of prospective data,”
Hepatology, vol. 52, no. 3, pp. 1156–1161, 2010.
[28] M. M. Mazeaud, F. Driss, K.-H. Le Quan Sang et al., “Biochem-
ical and functional alterations associated with hypercholes-
terolemia in platelets from hypertensive patients,” Atherosclero-
sis, vol. 94, no. 2-3, pp. 201–211, 1992.
[29] A. Icli, F. Aksoy, G. Nar et al., “Increased mean platelet volume
in familial hypercholesterolemia,” Angiology, vol. 67, no. 2, pp.
146–150, 2016.
[30] C. J. Boos and G. Y. Lip, “Assessment of mean platelet volume
in coronary artery disease—what does it mean?” Thrombosis
Research, vol. 120, no. 1, pp. 11–13, 2007.
[31] H. Wang, Z.-H. Wang, J. Kong et al., “Oxidized low-density
lipoprotein-dependent platelet- derived microvesicles trigger
procoagulant effects and amplify oxidative stress,” Molecular
Medicine, vol. 18, no. 2, pp. 159–166, 2012.
[32] A. Ghosh, G. Murugesan, K. Chen et al., “Platelet CD36
surface expression levels affect functional responses to oxidized
LDL and are associated with inheritance of specific genetic
polymorphisms,” Blood, vol. 117, no. 23, pp. 6355–6366, 2011.
[33] S. Nomura, A. Shouzu, S. Omoto, M. Nishikawa, T. Iwasaka,
and S. Fukuhara, “Activated platelet and oxidized LDL induce
endothelial membrane vesiculation: clinical significance of
endothelial cell-derived microparticles in patients with type 2
diabetes,” Clinical and Applied Thrombosis/Hemostasis, vol. 10,
no. 3, pp. 205–215, 2004.
[34] B. Klop, J. W. F. Elte, and M. C. Cabezas, “Dyslipidemia in
obesity: mechanisms and potential targets,”Nutrients, vol. 5, no.
4, pp. 1218–1240, 2013.
[35] N. A. Englyst, J. M. Taube, T. J. Aitman, T. P. Baglin, and C.
D. Byrne, “A novel role for CD36 in VLDL-enhanced platelet
activation,” Diabetes, vol. 52, no. 5, pp. 1248–1255, 2003.
[36] P. Lundman, M. J. Eriksson, A. Silveira et al., “Relation of
hypertriglyceridemia to plasma concentrations of biochemi-
cal markers of inflammation and endothelial activation (C-
reactive protein, interleukin-6, soluble adhesion molecules,
von Willebrand factor, and endothelin-1),” American Journal of
Cardiology, vol. 91, no. 9, pp. 1128–1131, 2003.
[37] M. Miller, N. J. Stone, C. Ballantyne et al., “Triglycerides and
cardiovascular disease: a scientific statement from the american
heart association,” Circulation, vol. 123, no. 20, pp. 2292–2333,
2011.
[38] K. Y. Stokes, D. Cooper, A. Tailor, and D. N. Granger, “Hyper-
cholesterolemia promotes inflammation and microvascular
dysfunction: role of nitric oxide and superoxide,” Free Radical
Biology and Medicine, vol. 33, no. 8, pp. 1026–1036, 2002.
[39] A. Castoldi, C. Naffah de Souza, N. O. S. Câmara, and P. M.
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